In The Media…

Authority Magazine

October 06, 2021

When creating the PrecisionPoint™ Transperineal Access System, Dr. Matthew Allaway sought to provide a biopsy option that would address many of the challenges associated with traditional biopsy approaches including pain, bleeding and urinary retention. The transperineal approach with PrecisionPoint results in nearly 30% better cancer detection rates and nearly a 0% infection rate (compared to a 5-7% infection rate with the transrectal approach).

prev   |  next

“More people are surviving cancer than ever before. Living with cancer is a reality, and we can still do most of the things we love to do while undergoing treatment.”

Dr. Matthew Allaway
Founder of Perineologic

Have a Question? Contact Us!

Thank you for your interest in Perineologic®!

Other Ways to Contact Us

ML-001-03revB